Denise mafra
Niterói, Rio de Janeiro, 24220-900, Brazil
NCT Number: NCT07596992
The aim of this project is to evaluate the effect of bioactive compound sources, propolis and royal jelly, on metabolomics, inflammation, and cardiovascular risk markers in participants with coronary artery disease. A longitudinal double-blind randomized clinical trial will be carried out, involving CAD participants for two months.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Niterói, Rio de Janeiro, 24220-900, Brazil
Several sources of bioactive compounds have been studied due to their protective effect against coronary artery disease (CAD), mainly by modulating inflammation and oxidative stress. Among them, propolis stands out, rich in flavonoids and phenolic acids, which exhibits antioxidant and anti-inflammatory activity; and royal jelly, containing bioactive peptides that promote endothelial function and have an anti-inflammatory effect, potentially contributing to the prevention of CAD progression. Regular consumption of these foods may represent a complementary therapeutic strategy for CAD prevention.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
They will receive 4 capsules per day, providing 300 mg of royal jelly per day and 500 mg of propolis per day.
They will receive 4 capsules per day, providing daily delivery of the active formulation vehicle (microcrystalline cellulose and magnesium stearate in colored gelatin capsules capable of masking the appearance of the internal contents).
Time frame: Baseline and 8 weeks
Get blood samples to evaluate the supplementation effects in inflammatory biomarkers: interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), C-reactive protein (CRP).
Contact information is provided by the study sponsor or research team.
Denise Mafra
CONTACT
Ludmila Cardozo
CONTACT
Universidade Federal Fluminense
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07596979
Arterial Occlusive Diseases, Arteriosclerosis
Rio de Janeiro, Brazil
View Trial DetailsNCT01625845
Arterial Occlusive Diseases, Arteriosclerosis
Indianapolis, Indiana, United States
View Trial DetailsNCT07357675
Arterial Occlusive Diseases, Arteriosclerosis
Rochester, Minnesota, United States
View Trial DetailsNCT07678021
Arterial Occlusive Diseases, Arteriosclerosis
Beijing, China
View Trial Details